title: Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.
abstract: ABSTRACT  This systematic review aims at assessment of the available evidence for systemic therapy options for patients with advanced gastrointestinal stromal tumors beyond first-line imatinib. Eligible trials were identified using databases search. In total, 26 studies were eligible and included in the final analysis. Among second-line studies, median progression-free survival ranged from 1.9 to 10 months while median overall survival ranged from 15 to 62 months. Among third-line agents, median progression-free survival ranged from 1.8 to 4.6 months while median overall survival ranged from 8.2 to 19 months. The available data for the second-line suggest that sunitinib is the best option while in the third line, regorafenib is the best option.
authors.affiliation: Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
authors.forename: Omar
authors.initials: O
authors.lastname: Abdel-Rahman
authors.affiliation: Medical Microbiology & Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
authors.forename: Mona
authors.initials: M
authors.lastname: Fouad
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000068877:Imatinib Mesylate
keywords: GIST; imatinib; salvage treatment; second line; systemic treatment; third line